CRCardiovascular Reviews3083-48802981-8109Bio-Byword Scientific Publishing Pty. Ltd.10.26689/cr.v4i2.14684ArticleThe Impact Analysis of Different Lipid-Lowering Regimens and Major Adverse Cardiovascular Events in ACS Patients after PCIhttps://artdesignp.com/journal/CR/4/2/10.26689/cr.v4i2.14684YeYin,LiTian,WangYan,JinWen2026422026-05-08Background and Objective: Intensive lipid-lowering therapy serves as a core intervention to improve the long-term prognosis of patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Currently, evidence-based clarification is still required for the efficacy discrepancies and applicable populations of three first-line lipid-lowering regimens: high-intensity statin monotherapy, statin plus ezetimibe, and statin plus proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i). This study aimed to systematically evaluate the impacts of these three regimens on major adverse cardiovascular events (MACE) in patients with ACS after PCI. Methods: We collected relevant randomized controlled trials (RCTs) and high-quality cohort studies on the three first-line regimens published from 2016 to 2022 worldwide. A random-effects model was adopted to analyze the risk of MACE in post-PCI ACS patients, and the therapeutic effects and sources of heterogeneity across different regimens were assessed. Results: Thirty-four studies with a total of 50,537 patients were finally included. The baseline characteristics were generally comparable between groups, and minor inter-group differences did not affect the analysis. (1) High-intensity statin significantly reduced the risk of MACE (RR = 0.52, 95% CI [0.37, 0.72], p < 0.0001), with pronounced benefits in Asian populations but no significant benefit in European and American populations. (2)          Statin combined with ezetimibe lowered the MACE risk (RR = 0.59, 95% CI [0.40, 0.86], p = 0.006), and the benefit was more significant in Asian populations and in patients with a follow-up duration of ≥12 months. (3) Statin combined with PCSK9i reduced the MACE risk (RR = 0.80, 95% CI [0.72, 0.89], p < 0.0001) with low heterogeneity, and the benefit was more prominent in Asian populations and on the basis of moderate-intensity statin. Only the high-intensity statin group presented a positive Egger test, which was a false positive driven by heterogeneity, and the pooled results were stable. Conclusion: All three intensive lipid-lowering regimens can reduce the risk of MACE in post-PCI ACS patients, with more significant benefits observed in Asian populations. Statin combined with PCSK9i shows a stable risk-reduction effect.

Rao S, O’donoghue M, Ruel M, et al., 2025, ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. JACC, 85(22): 2135–2237.

Byrne R, Rossello X, Coughlan J, et al., 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. European Heart Journal, 44(38): 3720–3826.

Mensink F, Los J, Reda Morsy M, et al., 2025, Changes in Non-Culprit Coronary Lesions with PCSK9 Inhibitors: The Randomised, Placebo-Controlled FITTER Trial. EuroIntervention, 21(16): 910–920.

Jernberg T, Hasvold P, Henriksson M, et al., 2015, Cardiovascular Risk in Post-Myocardial Infarction Patients: Nationwide Real World Data Demonstrate The Importance of a Long-Term Perspective. Eur Heart J, 36(19): 1163–70.

Brie D, Mornoș C, Adam O, et al., 2025, Dyslipidemia Treatment in Patients with Acute Coronary Syndrome: Is It Time to Move to Combination Therapy? Journal of Clinical Medicine, 14(18): 6445.

Wang Z, Liu J, Li J, et al., 2023, Chinese Guidelines for Lipid Management (2023). Chinese Circulation Journal, 38(3): 237–271.

Higgins J, Altman D, Gøtzsche P, et al., 2011, The Cochrane Collaboration’s Tool for Assessing Risk of Bias In Randomised Trials. BMJ, 2011(343): d5928.

Stang A, 2010, Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. Eur J Epidemiol, 25(9): 603–605.

He W, Cao M, Li Z, 2020, Effects of Different Doses of Atorvastatin, Rosuvastatin, and Simvastatin on Elderly Patients with ST‐Elevation Acute Myocardial Infarction (AMI) after Percutaneous Coronary Intervention (PCI). Drug Development Research, 81(5): 551–556.

Im E, Cho Y, Suh Y, et al., 2018, High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study. Revista Española de Cardiología (English Edition), 71(6): 423–431.

Liu Q, Wang Y, Cheng X, 2019, The Functional Effect of Atorvastatin Dose-Dependent via Inflammation Factors on Acute St Segment Elevation Myocardial Infarction after Emergency Percutaneous Coronary Intervention. Journal of Cardiovascular Medicine, 20(4): 215–219.

Liu Z, Joerg H, Hao H, et al., 2016, Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention. Annals of Pharmacotherapy, 50(9): 725–733.

Ran D, Nie H, Gao Y, et al., 2017, A Randomized, Controlled Comparison of Different Intensive Lipid-Lowering Therapies in Chinese Patients With Non-St-Elevation Acute Coronary Syndrome (Nste-Acs): Ezetimibe and Rosuvastatin versus High-Dose Rosuvastatin. International Journal of Cardiology, 2017(235): 49–55.

Guo J, Zhang W, Zhao Q, et al., 2017, Study on the Effect of Different doses of Rosuvastatin on Ventricular Remodeling in Patients with Acute Coronary Syndrome after Emergency Percutaneous Coronary Intervention. Eur Rev Med Pharmacol Sci, 21(19): 4457–4463.

Li Y, Lin H, 2017, Effect of Intensive Atorvastatin Therapy on Long-Term Prognosis of Patients with Acute Coronary Syndrome after PCI. Heilongjiang Medicine Journal, 30(3): 556–557.

Yuan X, Huang Z, Hong C, et al., 2018, Effect of Statin Combined with Ezetimibe on Patients with Acute Coronary Syndrome after PCI. Journal of Practical Medicine, 34(10): 1708–1711.

Xu X, Chai M, Cheng Y, et al., 2021, Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome. Curr Vasc Pharmacol, 19(4): 429–437.

Furtado R, Fagundes A, Oyama K, et al., 2022, Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circulation-Cardiovascular Interventions, 15(3): e011382.

Koskinas K, Windecker S, Pedrazzini G, et al., 2019, Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). Journal of the American College of Cardiology, 74(20): 2452–2462.

Leucker T, Blaha M, Jones S, et al., 2020, Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period. Circulation, 142(4): 419–421.

Mehta S, Pare G, Lonn E, et al., 2022, Effects of Routine Early Treatment with PCSK9 Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Randomised, Double-Blind, Sham-Controlled Trial. EuroIntervention, 18(11): e888–e896.

Okada T, Miyoshi T, Doi M, et al., 2022, Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial. Journal of Cardiovascular Development and Disease, 9(5): 153.

Räber L, Ueki Y, Otsuka T, et al., 2022, Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. JAMA, 327(18): 1771.

Zhang Y, Zhang Y, Zhang B, et al., 2022, Early Initiation of Evolocumab Treatment in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Clinical Therapeutics, 44(6): 901-912.

Berwanger O, Santucci E, De Barros E Silva P, et al., 2018, Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA, 319(13): 1331–1340.

Deng Y, He S, Wang D, et al., 2021, Clinical Study on the Effects of Ezetimibe Combined with Statins on Remnant Lipoprotein-Cholesterol and MACE in Patients with Acute Coronary Syndrome Undergoing Emergency PCI. Chinese Journal of Clinical Pharmacology and Therapeutics, 26(9): 1048–1052.

Sun C, Zheng W, Liang L, et al., 2021, Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI. Journal of Interventional Cardiology, 2021(2021): 1–7.

Hibi K, Sonoda S, Kawasaki M, et al., 2018, Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome. Circulation Journal, 82(3): 757–766.

Dai Y, Zhang H, Zhang X, et al., 2017, Statin-Ezetimibe versus Statin Lipid-Lowering Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of Thoracic Disease, 9(5): 1345–1352.

Schwartz G, Steg P, Szarek M, et al., 2018, Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 379(22): 2097–2107.

Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al., 2017, Low-Density Lipoprotein Cholesterol Targeting with Pitavastatin + Ezetimibe For Patients with Acute Coronary Syndrome and Dyslipidaemia: The HIJ-PROPER Study, A Prospective, Open-Label, Randomized Trial. European Heart Journal, 38(29): 2264–2276.

Li J, 2022, Effects Of Different Doses of Atorvastatin Calcium in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention. Electronic Journal of Integrated Traditional Chinese and Western Medicine on Cardiovascular Diseases, 10(24): 64–66+73.

Wei J, Zhang X, 2020, Application Effects of Different Doses of Atorvastatin after Interventional Therapy for Acute Coronary Syndrome and its Impact on Lipid-Lowering and Vascular Function. Clinical Research and Practice, 5(16): 50–52.

Feng X, 2019, Clinical Observation of Ezetimibe Combined with Rosuvastatin in Patients after PCI, thesis, Air Force Military Medical University.

Jin Y, Han D, Xu X, et al., 2019, Study on the Effects of Different Doses of Statin Drugs on the Efficacy of Acute Myocardial Infarction. Journal of Hunan Normal University (Medical Sciences), 16(6): 67–69.

Liu H, Zhang X, 2020, Clinical Analysis of the Effects of Different Doses of Atorvastatin on Early Blood Lipids and Recent Cardiovascular Events after Coronary Artery Intervention in Patients with Acute Myocardial Infarction. Electronic Journal of Clinical Medical Literature, 7(2): 141+161.

Zhang C, Guo S, Zhang Y, et al., 2022, Application Effect of Ezetimibe Combined with Rosuvastatin in Patients with Acute Coronary Syndrome after PCI. Internal Medicine, 17(4): 403–407.

Cai J, 2022, Study On The Efficacy Of Evolocumab Combined With Moderate-Dose Statin Therapy In Patients With Acute Coronary Syndrome, thesis, Tianjin Medical University.

Yang L, 2022, Clinical Study on the Effects of Evolocumab on Lipid Metabolism and Carotid Atherosclerosis in Patients with Acs undergoing PCI, thesis, Henan University.

Chen Z, Zhu Z, Sheng X, 2020, Analysis of the Efficacy of Rosuvastatin Combined with Ezetimibe in Patients with Acute Myocardial Infarction. Journal of Practical Clinical Medicine, 24(18): 26–29.

Zhao J, Li W, Zheng Y, et al., 2022, Effects of Alirocumab Combined with Rosuvastatin on Coronary Microcirculation, Inflammation, and Cardiac Function in Patients with Acute Myocardial Infarction after PCI. Journal of Clinical and Experimental Medicine, 21(24): 2606–2610.

Yang H, Chen Y, Wei G, et al., 2020, Application Effect of PCSK9 Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Chinese Heart Journal, 32(5): 480–484.

Cannon C, Blazing M, Giugliano R, et al., 2015, Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 372(25): 2387–2397.

Sabatine M, Giugliano R, Keech A, et al., 2017, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 376(18): 1713–1722.